2. Academic Validation
  3. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives

Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives

  • Bioorg Med Chem Lett. 2004 Sep 20;14(18):4627-31. doi: 10.1016/j.bmcl.2004.07.010.
Patrick Bernardelli 1,  Edwige Lorthiois,  Fabrice Vergne,  Chrystelle Oliveira,  Abdel-Kader Mafroud,  Emmanuelle Proust,  Nga Pham,  Pierre Ducrot,  François Moreau,  Moulay Idrissi,  Anita Tertre,  Bernadette Bertin,  Magali Coupe,  Eric Chevalier,  Arnaud Descours,  Françoise Berlioz-Seux,  Patrick Berna,  Mei Li
Affiliations

Affiliation

  • 1 Pfizer Global Research and Development, 3-9 rue de la Loge 94265 Fresnes, France. [email protected]
PMID: 15324877 DOI: 10.1016/j.bmcl.2004.07.010
Abstract

The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented.

Figures